Inozyme Pharma Ownership | Who Owns Inozyme Pharma?
Inozyme Pharma Ownership Summary
Inozyme Pharma is owned by 35.11% institutional investors, 1.31% insiders, and 63.58% retail investors. Adage capital partners gp is the largest institutional shareholder, holding 8.15% of INZY shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 3.46% of its assets in Inozyme Pharma shares.
INZY Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Inozyme Pharma | 35.11% | 1.31% | 63.58% |
| Sector | Healthcare Stocks | 57.39% | 9.93% | 32.68% |
| Industry | Biotech Stocks | 68.48% | 9.65% | 21.87% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Adage capital partners gp | 5.16M | 8.15% | $14.29M |
| Pivotal bioventure partners investment advisor | 4.49M | 7.10% | $12.45M |
| Sofinnova investments | 4.28M | 6.76% | $11.86M |
| Affinity asset advisors | 3.97M | 6.28% | $11.00M |
| Rock springs capital management lp | 3.86M | 6.10% | $10.70M |
| Blackrock funding, inc. /de | 3.81M | 6.03% | $10.56M |
| Blackrock | 3.34M | 5.41% | $14.91M |
| Vanguard group | 2.63M | 4.16% | $7.29M |
| Nea management company | 2.44M | 3.85% | $6.75M |
| Eventide asset management | 2.22M | 3.51% | $6.15M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Pivotal bioventure partners investment advisor | 4.49M | 8.41% | $12.45M |
| Saturn v capital management | 1.37M | 1.49% | $3.81M |
| Affinity asset advisors | 3.97M | 1.47% | $11.00M |
| Sofinnova investments | 4.28M | 0.86% | $11.86M |
| Sanofi | 443.25K | 0.70% | $1.23M |
| Knott david m jr | 695.00K | 0.70% | $1.93M |
| Blue owl capital lp | 1.08M | 0.69% | $2.99M |
| Sphera funds management | 1.19M | 0.60% | $3.30M |
| Samsara biocapital | 1.56M | 0.59% | $4.33M |
| Rock springs capital management lp | 3.86M | 0.41% | $10.70M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Affinity asset advisors | 3.97M | 1.47% | 1.15M |
| Sanofi | 443.25K | 0.70% | 443.25K |
| Blackrock funding, inc. /de | 3.81M | 0.00% | 321.30K |
| Renaissance | 421.40K | 0.00% | 256.60K |
| Blackrock | 3.34M | 0.00% | 254.54K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Samlyn capital | - | - | -3.26M |
| Eventide asset management | 2.22M | 0.11% | -1.91M |
| Fmr | 1.82M | 0.00% | -654.23K |
| Adage capital partners gp | 5.16M | 0.03% | -513.63K |
| Kennedy capital management | - | - | -437.66K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Sanofi | 443.25K | 0.70% | 443.25K | $1.23M |
| Walleye capital | 237.62K | 0.00% | 237.62K | $658.21K |
| Abrdn | 170.52K | 0.00% | 170.52K | $472.35K |
| Jump financial | 89.29K | 0.01% | 89.29K | $247.34K |
| Adar1 capital management | 76.30K | 0.04% | 76.30K | $211.35K |
Sold Out
| Holder | Change |
|---|---|
| Nelson, van denburg & campbell wealth management group | -9.00 |
| Gamma investing | -27.00 |
| Capital performance advisors llp | -35.00 |
| Us bancorp \de\ | -44.00 |
| Advisor group | -50.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 56 | -37.78% | 22,214,256 | -59.31% | 35 | 0.47% | 38 | -15.56% | 6 | -72.73% |
| Sep 30, 2024 | 89 | -3.26% | 54,577,497 | 1.39% | 86 | 1.14% | 44 | -22.81% | 22 | 15.79% |
| Jun 30, 2024 | 91 | - | 53,828,169 | 7.93% | 87 | 0.94% | 57 | 39.02% | 18 | -41.94% |
| Mar 31, 2024 | 91 | 9.64% | 49,874,140 | -0.33% | 96 | 1.24% | 41 | -22.64% | 31 | 106.67% |
| Dec 31, 2023 | 83 | 2.47% | 50,036,907 | 2.76% | 88 | 0.75% | 53 | 20.45% | 15 | -25.00% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Eventide Healthcare & Life Sciences I | 2.22M | 3.46% | -1.91M |
| Vanguard Total Stock Mkt Idx Inv | 1.67M | 2.59% | 108.95K |
| Vanguard US Total Market Shares ETF | 1.56M | 2.43% | - |
| iShares Russell 2000 ETF | 1.36M | 2.11% | -11.77K |
| Fidelity Select Biotechnology | 1.17M | 1.81% | -311.00K |
| Vanguard Institutional Extnd Mkt Idx Tr | 679.65K | 1.06% | - |
| Fidelity Small Cap Index | 521.06K | 0.81% | -9.76K |
| iShares Russell 2000 Value ETF | 466.26K | 0.73% | - |
| abrdn Life Sciences Investors | 326.76K | 0.51% | - |
| State St Russell Sm/Mid Cp® Indx NL Cl C | 318.10K | 0.50% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Apr 02, 2025 | Treco Douglas A | CEO & Chairman | Sell | $7.85K |
| Apr 02, 2024 | Treco Douglas A | CEO | Sell | $52.21K |
| Aug 01, 2023 | Pivotal bioVenture Partners Fund I, L.P. | - | Buy | $3.43M |
| Aug 01, 2023 | Pivotal bioVenture Partners Fund I, L.P. | - | Buy | $571.43K |
| Aug 01, 2023 | Hopfner Robert Lorne | - | Buy | $3.43M |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q2 | - | 1 |
| 2025 Q1 | - | - |
| 2024 Q4 | - | - |
| 2024 Q3 | - | - |
| 2024 Q2 | - | 1 |
INZY Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools